Aleks Engel

Aleks joined Novo Holdings A/S in 2014 and is Partner in the Planetary Health Investments team.
Aleks also leads Novo Holdings’ REPAIR Impact Fund targeting antimicrobial resistance.

Prior to joining Novo Holdings, Aleks was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).

Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.